Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Psilocybin for Chronic Pelvic Pain in Women
NCT06988319Phase 1Recruiting
- Sponsor
- Oregon Health & Science University
- Start
- Nov 2026
- Primary completion
- Dec 2027
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of psilocybin in chronic pelvic pain (CPP), sponsored by Oregon Health & Science University. Primary endpoints: Recruitment and Retention Feasibility at 1 month, Acceptability at 1 month and 1 more. Started Nov 2026; status: recruiting.
02
Drugs
psilocybin
03
Conditions
chronic pelvic pain (CPP)
Beyond the preview
Go deeper on NCT06988319.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06988319.